المؤلفون: Roubaud, Guilhem, Özgüroğlu, M., Penel, Nicolas, Matsubara, N., Mehra, N., Kolinsky, M. P., Procopio, G., Feyerabend, S., Joung, J. Y., Gravis, Gwenaelle, Nishimura, K., Gedye, C., Padua, C., Shore, N., Thiery-Vuillemin, Antoine, Saad, F., Van Alphen, R., Carducci, M. A., Desai, C., Brickel, N., Poehlein, C., Del Rosario, P., Fizazi, Karim

المساهمون: Université de Lille, CHU Lille, Institut Bergonié Bordeaux, Centre Régional de Lutte contre le Cancer Oscar Lambret Lille UNICANCER/Lille, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Institut Paoli-Calmettes IPC, Centre Hospitalier Régional Universitaire de Besançon CHRU Besançon, Institut Gustave Roussy IGR

مصطلحات موضوعية: PROfound, Metastatic castration-resistant prostate, cancer, Olaparib, Safety, Adverse-event management

وصف الملف: application/octet-stream; application/rdf+xml; charset=utf-8; application/pdf

العلاقة: European Journal of Cancer; Eur J Cancer; http://hdl.handle.net/20.500.12210/90084Test

الإتاحة: https://doi.org/20.500.12210/90084Test
https://hdl.handle.net/20.500.12210/90084Test

المؤلفون: Saad, F., Clarke, Noel W, Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J. Y., Sugimoto, M., Sartor, O., Liu, Y. Z., Poehlein, C., Barker, L., Del Rosario, P. M., Armstrong, A. J.

المساهمون: Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

العلاقة: https://doi.org/10.1016/s1470-2045Test(23)00382-0; Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. The Lancet Oncology. 2023 Sep 12. PubMed PMID: 37714168. Epub 2023/09/16. eng.; http://hdl.handle.net/10541/626564Test; Lancet Oncology

الإتاحة: https://doi.org/10.1016/s1470-2045Test(23)00382-0
http://hdl.handle.net/10541/626564Test

المؤلفون: Oya, M., Armstrong, A. J., Thiery-Vuillemin, A., Shore, N., Procopio, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlurmann, F. C., Joung, J. Y., Sugimoto, M., Sartor, O., Liu, Y. Z., Poehlein, C. H., Desai, C., Del Rosario, P. M. D., Clarke, Noel W, Saad, F.

المساهمون: Department of Urology, Keio University School of Medicine, Shinjuku-ku, Japan

العلاقة: https://dx.doi.org/10.1016Test/j.annonc.2022.10.194; Oya M, Armstrong AJ, Thiery-Vuillemin A, Shore N, Procopio G, Arslan C, et al. Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Nov;38(9):S1495-S. PubMed PMID: WOS:000897943700159.; http://hdl.handle.net/10541/626139Test; Annals of Oncology

الإتاحة: https://doi.org/10.1016Test/j.annonc.2022.10.194
http://hdl.handle.net/10541/626139Test

المؤلفون: Saad, F., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N. D., Procopio, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlurmann, F. C., Joung, J. Y., Sugimoto, M., Sartor, O., Liu, Y. Z., Poehlein, C. H., Desai, C., Del Rosario, P. M. D., Clarke, Noel W

المساهمون: Department Of Urology, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, H2X 3J4

العلاقة: https://dx.doi.org/10.1016/annonc/annonc1070Test; Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore ND, Procopio G, et al. Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Sep;33(7):S1160-S. PubMed PMID: WOS:000866211601614.; http://hdl.handle.net/10541/625972Test; Annals of Oncology

الإتاحة: https://doi.org/10.1016/annonc/annonc1070Test
http://hdl.handle.net/10541/625972Test

المؤلفون: Saad, F., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Loredo, E., Procopio, G., de Menezes, J. J., Girotto, G. C., Arslan, C., Parnis, N. M. F., Parnis, F., Brown, E., Schlurmann, F., Joung, J. Y., Sugimoto, M., Poehlein, C. H., Harrington, E., Desai, C., Kang, J. Y., Clarke, Noel W

المساهمون: Centre Hospitalier de l’Université de Montréal/CRCHUM, Montreal, QC, Canada

العلاقة: https://dx.doi.org/10.1200/JCO.2022.40.6_suppl.011Test; Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Loredo E, Procopio G, et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Vol. 40, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 11–11.; http://hdl.handle.net/10541/625248Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2022.40.6_suppl.011Test
http://hdl.handle.net/10541/625248Test

المؤلفون: Park, S M, Joung, J Y, Cho, Y Y, Sohn, S Y, Hur, K Y, Kim, J H, Kim, S W, Chung, J H, Lee, M K, Min, Y-K

المصدر: European Journal of Clinical Nutrition ; volume 69, issue 3, page 361-366 ; ISSN 0954-3007 1476-5640

مصطلحات موضوعية: Nutrition and Dietetics, Medicine (miscellaneous)

الإتاحة: https://doi.org/10.1038/ejcn.2014.284Test
https://www.nature.com/articles/ejcn2014284Test
https://www.nature.com/articles/ejcn2014284.pdfTest

المؤلفون: Kolinsky, M. P., Roubaud, G., ÖZGÜROĞLU, Mustafa, Penel, N., Matsubara, N., Mehra, N., Procopio, G., Feyerabend, S., Joung, J. Y., Gravis, G., Nishimura, K., Gedye, C., Padua, C., Shore, N., Thiery-Vuillemin, A., Gresty, C., Brickel, N., Burgents, J., Allen, A., Fizazi, K.

المساهمون: UNICANCER ,, 2286927

مصطلحات موضوعية: ONKOLOJİ, Klinik Tıp, Klinik Tıp (MED), Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji

العلاقة: Roubaud G., ÖZGÜROĞLU M., Penel N., Matsubara N., Mehra N., Kolinsky M. P. , Procopio G., Feyerabend S., Joung J. Y. , Gravis G., et al., "Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound", ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31; av_9f0f7fcd-6c33-4d62-bf26-256d93e82eb0; vv_1032021; http://hdl.handle.net/20.500.12627/3575Test; https://doi.org/10.1016Test/j.annonc.2020.08.883; 31

الإتاحة: https://doi.org/20.500.12627/3575Test
https://doi.org/10.1016Test/j.annonc.2020.08.883
https://hdl.handle.net/20.500.12627/3575Test

المؤلفون: Han, K S, Joung, J Y, Kim, T S, Jeong, I G, Seo, H K, Chung, J, Lee, K H

المصدر: British Journal of Cancer ; volume 98, issue 1, page 86-90 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/sj.bjc.6604113Test
http://www.nature.com/articles/6604113.pdfTest
http://www.nature.com/articles/6604113Test

المؤلفون: Oh, N. S., Lee, J. Y., Joung, J. Y., Shin, Y. K.

المصدر: Journal of Animal Science ; volume 94, issue suppl_5, page 249-250 ; ISSN 0021-8812 1525-3163

مصطلحات موضوعية: Genetics, Animal Science and Zoology, General Medicine, Food Science

الإتاحة: https://doi.org/10.2527/jam2016-0521Test
http://academic.oup.com/jas/article-pdf/94/suppl_5/249/23337205/249b.pdfTest

المؤلفون: Oh, N. S., Lee, J. Y., Joung, J. Y., Kim, S. G., Shin, Y. K.

المصدر: Journal of Animal Science ; volume 94, issue suppl_5, page 264-264 ; ISSN 0021-8812 1525-3163

مصطلحات موضوعية: Genetics, Animal Science and Zoology, General Medicine, Food Science

الإتاحة: https://doi.org/10.2527/jam2016-0554Test
http://academic.oup.com/jas/article-pdf/94/suppl_5/264/23337547/264a.pdfTest